A new study shows that a sustainable faecal microbiota transplantation (FMT) treatment protocol, including anaerobic sample preparation, induces remission of active ulcerative colitis. The promising results are another piece in the puzzle, but it is not yet possible to draw conclusions and implement the procedure in clinical practice.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A single-cell nanocoating of probiotics for enhanced amelioration of antibiotic-associated diarrhea
Nature Communications Open Access 19 April 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cammarota, G. et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 66, 569–680 (2017).
Cammarota, G. et al. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy. Pharmacol. Ther. 149, 191–212 (2015).
Harbord, M. et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J. Crohns Colitis 11, 769–784 (2017).
Costello, S. P. et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis. A randomized clinical trial. JAMA 321, 156–164 (2019).
Moayyedi, P. et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149, 102–109 (2015).
Rossen, N. G. et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 149, 110–118 (2015).
Paramsothy, S. et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389, 1218–1228 (2017).
Sandborn, W. J. et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146, 85–95 (2014).
Feagan, B. G. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369, 699–710 (2013).
Damman, C. J. et al. Low level engraftment and improvement following a single colonoscopic administration of fecal microbiota to patients with ulcerative colitis. PLOS ONE 10, e0133925 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Cammarota, G., Ianiro, G. FMT for ulcerative colitis: closer to the turning point. Nat Rev Gastroenterol Hepatol 16, 266–268 (2019). https://doi.org/10.1038/s41575-019-0131-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-019-0131-0
This article is cited by
-
A single-cell nanocoating of probiotics for enhanced amelioration of antibiotic-associated diarrhea
Nature Communications (2022)
